secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2022-04-27T23:59:59+00:00
Accession:  0000917520-22-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q1 adjusted EPS $0.74 beats prior year; raises FY organic growth guidance to 3.8%-5.2%
--------------------------------------------------------------------------------

- Revenues $376.6M (+4.6% reported, +5.6% organic); adjusted EPS $0.74 vs $0.69 Q1 2021; GAAP EPS $0.39 (down from $0.53, prior year included $42.9M divestiture gain).
- Codman Specialty Surgical rev $247.3M (org +5.0%); Tissue Technologies $129.3M (org +6.9%).
- FY 2022 organic growth guidance raised to 3.8%-5.2% (from 3.5%-5.0%); reported revenue reaffirmed $1.58B-$1.60B; adjusted EPS reaffirmed $3.27-$3.35.
- Board authorized new $225M share repurchase program (expires Dec 2024), replacing prior $225M program; completed $125M ASR in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000021/0000917520-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752022000021/iart-20220426.htm
  HTML page:      https://secwatch.observer/filing/0000917520-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer